Publications & Reference List

mRNA Therapeutics

Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D. (2017). Nature. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Mar 9; 543(7644):248-251.

Poleganov, M.A., Eminli, S., Beissert, T., Herz, S., Moon, J.I., Goldmann, J., Beyer, A., Heck, R., Burkhart, I., Barea Roldan, D., et al. (2015). Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. Hum Gene Ther. Nov; 26(11):751-766.

Kowalska, J., Wypijewska del Nogal, A., Darzynkiewicz, Z.M., Buck, J., Nicola, C., Kuhn, A.N., Lukaszewicz, M., Zuberek, J., Strenkowska, M., Ziemniak, M., et al. (2014). Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic Acids Res. 42(16):10245-10264.

Sahin, U., Kariko, K., and Tureci, O. (2014). mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. Oct; 13(10):759-780.

Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C.M., Huber, C., Tureci, O., and Sahin, U. (2010). Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. Nov 15; 70(22):9031-9040.

Individualized Cancer Immunotherapy

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. Jul 13; 547(7662):222-226. 

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. Jun 1; 534(7607):396-401.

Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M., Diekmann, J., Boegel, S., Schrors, B., Vascotto, F., Castle, J.C., et al. (2015). Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. Apr 30; 520(7549):692-696.

Castle, J.C., Loewer, M., Boegel, S., de Graaf, J., Bender, C., Tadmor, A.D., Boisguerin, V., Bukur, T., Sorn, P., Paret, C., et al. (2014). Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 15:190.

Castle, J.C., Kreiter, S., Diekmann, J., Lower, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012). Exploiting the mutanome for tumor vaccination. Cancer Res. Mar 1; 72(5):1081-1091.

Antibodies

Schumacher, J., Bacic, T., Staritzbichler, R., Daneschdar, M., Klamp, T., Arnold, P., Jägle, S., Türeci, Ö., Markl, J. and Sahin, U. (2018). Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide. Journal of nanobiotechnology16(1), 39. doi:10.1186/s12951-018-0363-0

Christiane R Stadler, Hayat Bähr-Mahmud, Laura M Plum, Kathrin Schmoldt, Anne C Kölsch, Özlem Türeci & Ugur Sahin (2015). Characterization of the First-in-Class T-Cell Engaging Bispecific Single-Chain Antibody for Targeted Immunotherapy of Solid Tumors Expressing the Oncofetal Protein Claudin 6.

Klamp, T., Schumacher, J., Huber, G., Kuhne, C., Meissner, U., Selmi, A., Hiller, T., Kreiter, S., Markl, J., Tureci, O., et al. (2011). Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer Res. Jan 15; 71(2):516-527.

Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H. (2010). Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta. J Mol Biol. 2010 Jan 8;395(1):167-75. doi: 10.1016/j.jmb.2009.10.028. Epub 2009 Oct 21. PMID: 19852971.

Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Wentzel A, Frauendorf H, Sommerhoff CP, Diederichsen U, Kolmar H. (2008). Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis. Chembiochem. 2008 Jan 4;9(1):33-7. PMID: 18058774.

Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. (2007): Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. FEBS J. 2007 Jan;274(1):86-95. Epub 2006 Nov 27. PMID: 17147697.